A new epigenetic therapy has shown potential for patients with recurrent metastatic non–small cell lung cancer (NSCLC), according to a recent issue of Cancer Discovery, a journal of the American Association for Cancer Research.
While disruptive and of growing concern to patients and clinicians, the current drug shortages in the US are limited mainly to generic injectables and a small number of disease areas, according to Drug Shortages: A Closer Look at Products, Suppliers and Volume Volatility, an IMS Institute for Healthcare Informatics study.
The report’s findings include:
Approximately half of male breast cancer patients treated with tamoxifen report side effects including weight gain and sexual dysfunction. These adverse effects influence more than 20% of male patients to discontinue treatment, according to researchers at The University of Texas MD Anderson Cancer Center. The study, published recently in Annals of Oncology, is the largest to date of how men with breast cancer tolerate the estrogen-blocking drug.
This week the US Food and Drug Administration (FDA) approved Erbitux (cetuximab) in combination with platinum-based chemotherapy with 5-fluorouracil (CT), for the first-line treatment of recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Head and neck cancers account for 3% to 5% of all cancers in the US, according to the National Cancer Institute. These cancers are more common in men and in people over the age of 50, and they typically develop in the nose, throat, or mouth.
Adequate information on fertility preservation may not be offered to many women prior to breast cancer treatment, according to research presented at the 2011 National Cancer Research Institute (NCRI) Cancer Conference.
A survey of more than 300 breast cancer surgeons, nurses, and cancer doctors was conducted by researchers at The Royal Free Hampstead NHS Trust to determine which factors impacted whether medical care providers discussed fertility preservation with their patients.
Patients diagnosed with metastatic breast cancer or ovarian cancer showed a positive response to treatment with a recombinant poxviral vaccine, according to a trial published in Clinical Cancer Research.
Lead researcher James Gulley, MD, PhD, director and deputy chief of the clinical trials group at the Laboratory of Tumor Immunology and Biology at the National Cancer Institute said, “With this vaccine, we can clearly generate immune responses that lead to clinical responses in some patients.”
New research shows that men experience more debilitating and often permanent side effects of prostate cancer when cancer treatment is coupled with poor lifestyle habits.
The study, presented at the 2011 National Cancer Research Institute (NCRI) Cancer Conference, found that men with prostate cancer suffered far more from side effects, including rectal bleeding, erectile dysfunction, and incontinence, if they were smokers, inactive, or overweight during and after radiotherapy.
Breast cancer drugs used to treat patients with high levels of HER2 may also be effective for head and neck cancers, according to research presented at the 2011 National Cancer Research Institute (NCRI) Cancer Conference this week.
Scientists at Massachusetts General Hospital Cancer Centre, Harvard Medical School, and the biotechnology firm Genentech scanned nearly 700 human cell lines from a range of cancer types and identified all cells that responded to lapatinib, a type of HER2 kinase inhibitor.
A major European study found that the risk of ovarian cancer is significantly diminished for women who take birth control pills for a decade or longer.
The study, published this week in the British Journal of Cancer, included more than 300,000 women enrolled in the European Prospective Investigation of Cancer and Nutrition. The women were taking the combination estrogen-progesterone oral contraceptive pill.
Fat cells in the omentum, a large fatty pad of tissue that drapes over the intestines in the abdomen, fuel the growth of ovarian cancer by supplying nutrients and energy for rapid tumor growth, reports a University of Chicago research team in the recent online publication of Nature Medicine.
To sign up for our newsletter or print publications, please enter your contact information below.
